Rifaximin in prevention and treatment of hepatic encephalopathy
Henryka Mięgoć | Marta Piekarska | Alicja D. Wandałowicz
⇒ Henryka Mięgoć, Klinika Chorób Zakaźnych i Hepatologii, Uniwersytecki Szpital Kliniczny w Białymstoku, ul. Żurawia 14, 15-540 Białystok, Tel./Fax: (85) 741 69 21
Forum Zakażeń 2013;4(3):217–221
Słowa kluczowe: amoniak | encefalopatia wątrobowa | rifaksymina
Abstract: Hepatic encephalopathy (HE) is one of the most common complications of acute and chronic liver diseases. HE affects significantly patient’s quality of life. HE prevention and treatment are based on avoidance of risk factors, manipulating the intestinal milieu and reducing the serum level of ammonia. Non-absorbable disaccharides account for basic therapy. Oral antibiotics such as neomycin and paromomycin are effective in therapy of HE acute episodes. However, using these antibiotics in prevention of recurrence of HE acute episodes is associated with severe side effects. Rifaximin is safe in long-term therapy what makes it useful in treatment and prevention of HE. A research has shown analogous therapeutic effect in use rifaximin and non-absorbable disaccharides. Use of rifaximin has been connected with fewer cases of side effects. Rifaximin is alternative treatment option in patients with poor tolerance to other treatment such as non-absorbable disaccharides and neomycin.
Key words: ammonia | hepatic encephalopathy | rifaximin